Advertisement

Topics

FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors

01:00 EDT 24 Aug 2017 | Hoffmann-La Roche Ltd

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for emicizumab prophylaxis (preventative) as a once-weekly subcutaneous treatment for adults, adolescents and children with haemophilia A with factor VIII inhibitors.

Original Article: FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors

NEXT ARTICLE

More From BioPortfolio on "FDA grants Priority Review to Roche’s emicizumab for haemophilia A with inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement